Is your melanoma hot enough for immunotherapy?

A new study shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.

Leave a Reply

Your email address will not be published. Required fields are marked *